No 'Unicorn' High-Cost/High-Volume Drugs Expected For 2017
This article was originally published in The Pink Sheet Daily
Executive Summary
Specialty drugs, which have been a key driver of health care spending growth in years past, are not expected to have the same impact in 2017 – mostly because there's no "unicorn" high-cost, high-volume blockbusters anticipated to enter the market next year.
You may also be interested in...
A New Year Filled With Debate Over Drug Pricing, PwC Predicts
Drug pricing and M&A top PwC’s Health Research Institute annual report highlighting the top issues impacting the health care sector in the year ahead.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.